Health
A novel monoclonal antibody therapy cuts LDL cholesterol by half in a high-risk patient population, – EurekAlert
The investigational drug evinacumab reduced low-density lipoprotein (LDL) cholesterol–the so-called ”bad” cholesterol–by 50 percent in patients with severe…
The investigational drug evinacumab reduced low-density lipoprotein (LDL) cholesterol–the so-called “bad” cholesterol–by 50 percent in patients with severe hypercholesterolemia whose condition is resistant to standard treatments, a phase 2 study from the Icahn School of Medicine of Mount Sinai and other global academic sites has found. Results from the study sponsored by Regeneron, are being presented as “late breaking science” at the American Heart Association Scientific Sessions 2020 on Sunday,…
-
Noosa News18 hours agoMotorbike rider dies after car collision at Kidaman Creek, west of Sunshine Coast
-
General19 hours agoDemocratic senators want an investigation into potential market manipulation from Trump’s inner circle
-
Business24 hours agoDown 20% this year, here are 3 reasons why I’m still loading up on Amazon stock
-
General24 hours agoStocks, dollar sink as trade war roils markets